STTR Phase I grants from NSF and National Cancer Institute to support development.
Funding for Phase 1 Ventures to support commercialization.
Exclusive worldwide license (option) from University of Pennsylvania for intellectual property.
Phase I allowed us to verify the performance of AAR for contouring of thoracic structures radiation therapy planning. We collaborated with radiation oncology at Penn Medicine to identify anatomical structures of interest, and developed prototype software for automatic contouring of head & neck cases.
In Phase II, we will continue development of AAR-RT, integrate it into an existing treatment planning tool, and offer it to additional academic medical centers for a prospective study. By the end of Phase II, we will have demonstrated the advantages of AAR-RT to manual contouring and other automated contouring approaches, and have thorough understanding of the requirements for workflow integration in initial contouring and adaptive planning.
The results of Phase II will be used to submit for FDA 510(k) clearance.
Expand AAR to identify and automatically contour tumor volume for adaptive radiation treatment planning.
Develop an automated method of disease progress and prognosis for whole-body systemic diseases (e.g. metastatic cancer).
We are constantly pushing our technology forward. Follow our progress.
Follow Our Progress